Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials

Two phase 3 placebo-controlled trials of the CYD-TDV vaccine, evaluated in children aged 2−14 y (CYD14) and 9−16 y (CYD15), demonstrated vaccine efficacy (VE) of 56.5% and 60.8%, respectively, against symptomatic virologically confirmed dengue (VCD). Sieve analyses were conducted to evaluate whether...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Proc Natl Acad Sci U S A
Glavni autori: Juraska, Michal, Magaret, Craig A., Shao, Jason, Carpp, Lindsay N., Fiore-Gartland, Andrew J., Benkeser, David, Girerd-Chambaz, Yves, Langevin, Edith, Frago, Carina, Guy, Bruno, Jackson, Nicholas, Duong Thi Hue, Kien, Simmons, Cameron P., Edlefsen, Paul T., Gilbert, Peter B.
Format: Artigo
Jezik:Inglês
Izdano: National Academy of Sciences 2018
Teme:
PNAS Plus
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6130398/
https://ncbi.nlm.nih.gov/pubmed/30127007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1714250115
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items